Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

May 3, 2021 Leave a comment
 A number of energetic vaccination approaches have confirmed ineffective in lowering the substantial morbidity and mortality attributable to respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a considerable and sustainable enhance in neutralising exercise is required to guard towards extreme RSV illness. To that finish, we evaluated the security and immunogenicity of DS-Cav1, a prefusion F subunit vaccine. On this part 1 research, DS-Cav1 vaccination was secure and effectively tolerated. DS-Cav1 vaccination elicited a strong enhance in RSV F-specific antibodies and neutralising exercise that was sustained above baseline for no less than 44 weeks.

On this randomised, open-label, part 1 scientific trial, the stabilised prefusion F vaccine DS-Cav1 was evaluated for dose, security, tolerability, and immunogenicity in wholesome adults aged 18-50 years at a single US web site. Individuals had been assigned to obtain escalating doses of both 50 μg, 150 μg, or 500 μg DS-Cav1 at weeks Zero and 12, and had been randomly allotted in a 1:1 ratio inside every dose group to obtain the vaccine with or with out aluminium hydroxide (AlOH) adjuvant. A single low-dose of pre-F immunisation of antigen-experienced people may confer safety that extends all through a complete RSV season.

After 71 individuals had been randomised, the protocol was amended to permit some individuals to obtain a single vaccination at week 0. The first goals evaluated the security and tolerability at each dose inside 28 days following every injection. Neutralising exercise and RSV F-binding antibodies had been evaluated from week Zero to week 44 as secondary and exploratory goals. Security was assessed in all individuals who acquired no less than one vaccine dose; secondary and exploratory immunogenicity evaluation included all individuals with out there knowledge at a given go to.

European knowledge sources for computing burden of (potential) vaccine-preventable illnesses in ageing adults

To information decision-making on immunisation programmes for ageing adults in Europe, one of many goals of the Vaccines and InfecTious illnesses within the Ageing popuLation (IMI2-VITAL) venture is to evaluate the burden of illness (BoD) of (doubtlessly) vaccine-preventable illnesses ((P)VPD). We aimed to establish the out there knowledge sources to calculate the BoD of (P)VPD in taking part VITAL international locations and to pinpoint knowledge gaps. Primarily based on epidemiological standards and vaccine availability, we prioritized (P) VPD attributable to Further-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia.

Morbidity and mortality knowledge had been typically out there for all 5 illnesses, whereas abstract BoD estimates had been largely missing. Out there knowledge weren’t all the time stratified by age and danger group, which is very necessary when calculating BoD for ageing adults. AMR knowledge had been out there in a number of international locations for S. aureus and ExPEC. This research offers an exhaustive overview of the out there knowledge sources and knowledge gaps for the estimation of BoD of 5 (P) VPD in ageing adults within the EU/EAA, which is helpful to information pathogen-specific BoD research and contribute to calculation of (P)VPDs BoD.

Respiratory syncytial virus (RSV) is a typical pathogen inflicting extreme respiratory sickness in infants and elder adults. The event of an efficient RSV vaccine is a crucial unmet medical want and an space of energetic analysis. The normal methodology for testing neutralizing antibodies towards RSV in scientific trials is the plaque discount neutralization take a look at (PRNT), which makes use of 24-well plates and wishes six days publish an infection to develop viral plaques.

On this research, we’ve got developed a virus discount neutralization take a look at (VRNT), which permits the variety of RSV contaminated cells to be routinely counted by an imaging cytometer at someday publish an infection in 96-well plates. VRNT was discovered sturdy to cell seeding density, detection antibody focus, virus enter and an infection time.

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Balancing Precision vs. Cohort Transcriptomic Evaluation of Acute and Restoration Part of Viral Bronchiolitis

Viral infections affecting the decrease respiratory tract place monumental burdens on hospitals. As neither vaccines nor anti-viral brokers exist for a lot of viruses, understanding danger elements and outcomes in every affected person utilizing minimally invasive evaluation, similar to blood, can result in improved healthcare supply. A cohort of PAXGene RNAseq of infants admitted with reasonable or extreme acute bronchiolitis and respiratory syncytial virus (RSV) had been in contrast with case-control statistical evaluation and cohort-based outlier mapping for precision transcriptomics.

Extreme bronchiolitis sufferers had signatures linked to the immune system, interferon signaling, and cytokine signaling, with marked intercourse variations in XIST, RPS4Y1, KDM5D, and LINC00278 for severity. A number of sufferers had distinctive secondary infections, cytokine activation, immune responses, organic pathways, and immune cell activation, highlighting the necessity for outlining patient-level transcriptomic signatures. Balancing relative contributions of cohort-based biomarker discoveries with affected person’s organic responses is required to grasp totality of mechanisms of hostile outcomes in viral bronchiolitis.

Orf Virus VEGF-E
MBS691891-0005mg 0.005mg
EUR 350

Orf Virus VEGF-E
MBS691891-5x0005mg 5x0.005mg
EUR 1275

Orf Virus VEGF-E
MBS691947-0002mg 0.002mg
EUR 265

Orf Virus VEGF-E
MBS691947-5x0002mg 5x0.002mg
EUR 890

VEGF E (Orf Virus)
cyt-263 2µg
EUR 60
Description: Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)

Anti-Orf Virus VEGF-E Antibody
102-PA70 50 µg
EUR 115.5
Description: A DNA sequence encoding the mature variant of ov-VEGF-E isolate D1701 was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight Cysteine residues of the central Cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins. Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E cannot bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.

Orf Virus VEGF-E, Heparin-binding
MBS691480-002mg 0.02mg
EUR 440

Orf Virus VEGF-E, Heparin-binding
MBS691480-5x002mg 5x0.02mg
EUR 1685

Orf Virus VEGF-E, Heparin-binding
MBS691994-0005mg 0.005mg
EUR 300

Orf Virus VEGF-E, Heparin-binding
MBS691994-5x0005mg 5x0.005mg
EUR 1050

Orf virus VEGF-E Recombinant Protein
300-044 5 µg
EUR 136.5
Description: A DNA sequence encoding the mature variant of ov-VEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight Cysteine residues of the central Cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E cannot bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.

Orf virus VEGF-E Recombinant Protein
300-044S 2 µg
EUR 73.5
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E can not bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.

Orf virus VEGF-E Recombinant Protein
300-045 20 µg
EUR 357
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E can not bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.

Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-1mg
QP10912-1mg 1mg
EUR 6181.2

Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-2ug
QP10912-2ug 2ug
EUR 186

Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-10ug
QP10912-10ug 10ug
EUR 241.2

Orf virus VEGF-E, Heparin-binding Recombinant Protein
300-046 20 µg
EUR 194.25
Description: A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701 (Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF165. The chimeric protein was expressed in insect cells using a baculovirus expression system. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor–2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin–1.

Orf virus VEGF-E, Heparin-binding Recombinant Protein
300-046S 5 µg
EUR 94.5
Description: A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701 (Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF165. The chimeric protein was expressed in insect cells using a baculovirus expression system. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor–2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin–1.

VEGF-E Vascular Endothelial Growth Factor-E Recombinant Protein(Orf Virus)
PROTQ2F842 Regular: 10ug
EUR 250
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa.

ov-VEGF-E (Orf virus) (Recombinant) Human
GWB-C8AD60 0.005 mg Ask for price

VEGFE protein (Orf virus)
30R-AV011 5 ug
EUR 381
Description: Purified recombinant VEGFE protein (Orf virus)

VEGFE protein (Orf virus)
MBS538323-0005mg 0.005mg
EUR 505

VEGFE protein (Orf virus)
MBS538323-5x0005mg 5x0.005mg
EUR 2125

Recombinant Orf Virus VEGFE Protein
VAng-Lsx0417-inquire inquire Ask for price
Description: Orf Virus VEGFE, recombinant protein from Baculovirus.

Recombinant Orf Virus VEGFE Protein [His]
VAng-Lsx0418-inquire inquire Ask for price
Description: Orf Virus VEGFE [His], recombinant protein from E. coli.

Cytochalasin E
C197-1MG 1 mg
EUR 79.77
Description: 36011-19-5

Cytochalasin E
C197-5MG 5 mg
EUR 276.58
Description: 36011-19-5

Chevalone E
C257-0.5MG 0.5 mg
EUR 153.46
Description: 1315451-94-5

Chevalone E
C257-2.5MG 2.5 mg
EUR 536.69
Description: 1315451-94-5

Berkeleylactone E
B087-1MG 1 mg
EUR 145.66
Description: 122211-62-5

Berkeleylactone E
B087-5MG 5 mg
EUR 509.81
Description: 122211-62-5

Deoxybrevianamide E
D083-1MG 1 mg
EUR 191.61
Description: 34610-68-9

Deoxybrevianamide E
D083-5MG 5 mg
EUR 670.21
Description: 34610-68-9

Oligomycin E
O021-1MG 1 mg
EUR 212.42
Description: 110231-34-0

Oligomycin E
O021-5MG 5 mg
EUR 741.31
Description: 110231-34-0

Paraherquamide E
P070-0.5MG 0.5 mg
EUR 271.38
Description: 125600-53-5

Paraherquamide E
P070-2.5MG 2.5 mg
EUR 947.66
Description: 125600-53-5

Phenelfamycin E
P078-1MG 1 mg
EUR 212.42
Description: 114451-31-9

Phenelfamycin E
P078-5MG 5 mg
EUR 741.31
Description: 114451-31-9

Roquefortine E
R035-1MG 1 mg
EUR 150
Description: 871982-52-4

Roquefortine E
R035-5MG 5 mg
EUR 524.55
Description: 871982-52-4

Anti-Hepatitis E Virus Antibody
18606 100ug
EUR 397

Azithromycin impurity E EvoPure®
A074-5MG 5 mg
EUR 605.18
Description: 612069-27-9

Anti-E (West Nile Virus) Antibody
MBS432133-01mg 0.1mg
EUR 355

Anti-E (West Nile Virus) Antibody
MBS432133-5x01mg 5x0.1mg
EUR 1440

Hepatitis E virus ORF 3 Recombinant Protein
53-335 0.01 mg
EUR 651.3
Description: Hepatitis E virus ORF 3 Recombinant Protein

Hepatitis E virus ORF 2 Recombinant Protein
53-336 0.01 mg
EUR 651.3
Description: Hepatitis E virus ORF 2 Recombinant Protein

Hepatitis E virus ORF 2 Recombinant Protein
53-337 0.01 mg
EUR 651.3
Description: Hepatitis E virus ORF 2 Recombinant Protein

Mouse Anti Hepatitis E Virus Capsid (ORF2) Antibody (EB2)
MAB12412-100 0.1
EUR 279.4
Description: Purified monoclonal antibody against Hepatitis E virus capsid (ORF2).

Mouse Anti Hepatitis E Virus Capsid (ORF2) Antibody (EB2)
MAB12412-500 0.5
EUR 699.15
Description: Purified monoclonal antibody against Hepatitis E virus capsid (ORF2).

Mouse Anti Hepatitis E Virus Capsid (ORF2) Antibody (BD6)
MAB12413-100 0.1
EUR 279.4
Description: Purified Monoclonal Antibody

Mouse Anti Hepatitis E Virus Capsid (ORF2) Antibody (BD6)
MAB12413-500 0.5
EUR 699.15
Description: Purified Monoclonal Antibody

Mouse Anti Hepatitis B Virus e-Virus Like Particle
MBS147314-01mg 0.1mg
EUR 360

Mouse Anti Hepatitis B Virus e-Virus Like Particle
MBS147314-05mg 0.5mg
EUR 960

Mouse Anti Hepatitis B Virus e-Virus Like Particle
MBS147314-1mg 1mg
EUR 1565

Mouse Anti Hepatitis B Virus e-Virus Like Particle
MBS147314-5x1mg 5x1mg
EUR 6715

Vascular Endothelial Growth Factor-E (Orf Virus) Protein
abx263083-10mg 10 mg
EUR 325

Vascular Endothelial Growth Factor-E (Orf Virus) Protein
20-abx263083
  • Ask for price
  • Ask for price
  • Ask for price
  • 2 µg
  • 10 ug
  • 1 mg

Vascular Endothelial Growth Factor-E (Orf Virus) Protein
abx263083-25mg 25 mg
EUR 6500

Vascular Endothelial Growth Factor-E (Orf Virus) Protein
abx263083-5mg 5 mg
EUR 225

Anti-Hepatitis B Virus "e" Antigen, mAb
MBS430104-01mg 0.1mg
EUR 355

Anti-Hepatitis B Virus "e" Antigen, mAb
MBS430104-5x01mg 5x0.1mg
EUR 1440

Anti-Hepatitis B Virus "e" Antigen, mAb
MBS430136-01mg 0.1mg
EUR 355

Anti-Hepatitis B Virus "e" Antigen, mAb
MBS430136-5x01mg 5x0.1mg
EUR 1440

Recombinant Vaccinia virus Uncharacterized 7.6 kDa protein (E ORF E)
MBS1007472-002mgBaculovirus 0.02mg(Baculovirus)
EUR 990

Recombinant Vaccinia virus Uncharacterized 7.6 kDa protein (E ORF E)
MBS1007472-002mgEColi 0.02mg(E-Coli)
EUR 555

Recombinant Vaccinia virus Uncharacterized 7.6 kDa protein (E ORF E)
MBS1007472-002mgYeast 0.02mg(Yeast)
EUR 745

Recombinant Vaccinia virus Uncharacterized 7.6 kDa protein (E ORF E)
MBS1007472-01mgEColi 0.1mg(E-Coli)
EUR 660

Recombinant Vaccinia virus Uncharacterized 7.6 kDa protein (E ORF E)
MBS1007472-01mgYeast 0.1mg(Yeast)
EUR 870

Anti-Hepatitis B Virus E Antigen Antibody
E38A9902 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-Hepatitis B Virus E Antigen Antibody
E38A9925 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-Hepatitis B Virus E Antigen Antibody
MBS4159320-01mg 0.1mg
EUR 635

Anti-Hepatitis B Virus E Antigen Antibody
MBS4159320-5x01mg 5x0.1mg
EUR 2610

Anti-Hepatitis B Virus E Antigen Antibody
MBS8241562-003mL 0.03mL
EUR 185

Anti-Hepatitis B Virus E Antigen Antibody
MBS8241562-01mL 0.1mL
EUR 255

Anti-Hepatitis B Virus E Antigen Antibody
MBS8241562-02mL 0.2mL
EUR 335

Anti-Hepatitis B Virus E Antigen Antibody
MBS8241562-5x02mL 5x0.2mL
EUR 1420

Anti-Hepatitis B Virus E Antigen Antibody
MBS8243145-003mL 0.03mL
EUR 185

Anti-Hepatitis B Virus E Antigen Antibody
MBS8243145-01mL 0.1mL
EUR 255

Anti-Hepatitis B Virus E Antigen Antibody
MBS8243145-02mL 0.2mL
EUR 335

Anti-Hepatitis B Virus E Antigen Antibody
MBS8243145-5x02mL 5x0.2mL
EUR 1420

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
7-01759 2µg Ask for price

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
7-01760 10µg Ask for price

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
7-01761 1mg Ask for price

Vascular Endothelial Growth Factor-E (Orf Virus), (Recombinant)
22060748-1 2 µg
EUR 190.94

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
cyt-263-10g 10µg
EUR 145

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
cyt-263-1mg 1mg
EUR 5100

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
cyt-263-2g 2µg
EUR 60

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
MBS142140-0002mg 0.002mg
EUR 240

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
MBS142140-001mg 0.01mg
EUR 310

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
MBS142140-1mg 1mg
EUR 5325

Recombinant Vascular Endothelial Growth Factor-E (Orf Virus)
MBS142140-5x1mg 5x1mg
EUR 23640

Vascular Endothelial Growth Factor-E Recombinant (Orf Virus)
rAP-2496 Inquiry Ask for price

Mouse Anti-Chikungunya Virus E Antibody (C4)
MAB12506-100 0.1
EUR 278.11
Description: Mouse monoclonal antibody against Chikungunya virus Envelope (E).

Anti-E (Zika Virus) Rabbit Polyclonal Antibody
MBS430184-01mg 0.1mg
EUR 370

Anti-E (Zika Virus) Rabbit Polyclonal Antibody
MBS430184-5x01mg 5x0.1mg
EUR 1525

Anti-Zika Virus Envelope Protein E Antibody
STJ503579 100 µg
EUR 571.2

Hepatitis E Virus antibody
70R-HR003 100 ug
EUR 295
Description: Affinity purified Rabbit polyclonal Hepatitis E Virus antibody

Hepatitis E Virus antibody
MBS534669-01mg 0.1mg
EUR 510

Hepatitis E Virus antibody
MBS534669-5x01mg 5x0.1mg
EUR 2145

Anti-Hepatitis B Virus E antigen Mouse mAb
MBS477398-01mL 0.1mL
EUR 450

Anti-Hepatitis B Virus E antigen Mouse mAb
MBS477398-5x01mL 5x0.1mL
EUR 1540

Hepatitis B virus e antigen (virus like particle)
MBS596081-1mg 1mg
EUR 425

Hepatitis B virus e antigen (virus like particle)
MBS596081-2mg 2mg
EUR 700

Hepatitis B virus e antigen (virus like particle)
MBS596081-5mg 5mg
EUR 1505

Hepatitis E Virus ORF3 Protein
20-abx260138
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 0.5 mg
  • 1 mg

Hepatitis E Virus ORF3 Protein
abx260138-20g 20 µg
EUR 950

Hepatitis E Virus ORF3 Protein
abx260138-5g 5 µg
EUR 350

Hepatitis E virus
8942 100 ug
EUR 340
Description: ORF 2

Hepatitis E virus
8943 100 ug
EUR 340
Description: ORF 2

Hepatitis E virus
8944 100 ug
EUR 340
Description: ORF 3

Hepatitis E virus
MBS328020-01mg 0.1mg
EUR 435

Hepatitis E virus
MBS328020-5x01mg 5x0.1mg
EUR 1865

Hepatitis E virus
MBS328021-01mg 0.1mg
EUR 435

Hepatitis E virus
MBS328021-5x01mg 5x0.1mg
EUR 1865

Hepatitis E virus
MBS328022-01mg 0.1mg
EUR 435

Hepatitis E virus
MBS328022-5x01mg 5x0.1mg
EUR 1865

Hepatitis E virus
PCR-H498-PCRH49848R PCR-H498-48R
EUR 485

Hepatitis E virus
PCR-H498-PCRH49896R PCR-H498-96R
EUR 685

Hepatitis E virus
Oneq-H498-OneqH498100R Oneq-H498-100R
EUR 1028

Hepatitis E virus
Oneq-H498-OneqH498150R Oneq-H498-150R
EUR 1438

Hepatitis E virus
Oneq-H498-OneqH49850R Oneq-H498-50R
EUR 728

Goat anti-Hepatitis B Virus E Antigen Antibody
DL95826A-100ul 100 ul
EUR 370
Description: Core antigen; Core protein; HBe antigen; HBeAg; HBVgp4; Pre C C; Precore protein; Precore/core; Precore/core ORF; Precore/core protei

Goat anti-Hepatitis B Virus E Antigen Antibody
DL95826A-50ul 50 ul
EUR 259
Description: Core antigen; Core protein; HBe antigen; HBeAg; HBVgp4; Pre C C; Precore protein; Precore/core; Precore/core ORF; Precore/core protei

Goat anti-Hepatitis B Virus E Antigen Antibody
YLD8369-100ul 100 ul
EUR 320
Description: Goat polyclonal antibody to Hepatitis B Virus E Antigen

Goat anti-Hepatitis B Virus E Antigen Antibody
YLD8369-50ul 50 ul
EUR 200
Description: Goat polyclonal antibody to Hepatitis B Virus E Antigen

Mouse anti-Hepatitis B Virus E Antigen Antibody
DL95804A-100ul 100 ul
EUR 370
Description: Core antigen; Core protein; HBe antigen; HBeAg; HBVgp4; Pre C C; Precore protein; Precore/core; Precore/core ORF; Precore/core protei

Mouse anti-Hepatitis B Virus E Antigen Antibody
DL95804A-50ul 50 ul
EUR 259
Description: Core antigen; Core protein; HBe antigen; HBeAg; HBVgp4; Pre C C; Precore protein; Precore/core; Precore/core ORF; Precore/core protei

Mouse anti-Hepatitis B Virus E Antigen Antibody
YLD8466-100ul 100 ul
EUR 320
Description: Mouse monoclonal antibody to Hepatitis B Virus E Antigen

Mouse anti-Hepatitis B Virus E Antigen Antibody
YLD8466-50ul 50 ul
EUR 200
Description: Mouse monoclonal antibody to Hepatitis B Virus E Antigen

Anti-Zika Virus Envelope Protein E Antibody FITC
STJ503581 100 µg
EUR 703.2

Recombinant Hepatitis E Virus ORF3 
7-07450 100µg Ask for price

Recombinant Hepatitis E Virus ORF3 
7-07451 500µg Ask for price

Recombinant Hepatitis E Virus ORF3 
7-07452 1000µg Ask for price

Hepatitis E Virus ORF3 (Recombinant)
22060181-1 100 µg
EUR 344.89

Recombinant Hepatitis E Virus ORF3 
MBS142588-01mg 0.1mg
EUR 330

Recombinant Hepatitis E Virus ORF3 
MBS142588-05mg 0.5mg
EUR 825

Recombinant Hepatitis E Virus ORF3 
MBS142588-1mg 1mg
EUR 1515

Recombinant Hepatitis E Virus ORF3 
MBS142588-5x1mg 5x1mg
EUR 6485

Hepatitis E Virus ORF3 Recombinant
rAP-5321 Inquiry Ask for price

anti- VEGF antibody
FNab09391 100µg
EUR 658.5
Description: Antibody raised against VEGF

Anti- VEGF antibody
FNab09933 100µg
EUR 658.5
Description: Antibody raised against VEGF

Respiratory Syncytial Virus (RSV) is the foremost explanation for decrease respiratory tract an infection in infants, in whom, the sensing of RSV by innate immune receptors and its regulation are nonetheless poorly described. Nevertheless, the extreme bronchiolitis following RSV an infection in neonates has been related to a defect in sort I interferons (IFN-I) manufacturing, a cytokine produced primarily by alveolar macrophages (AMs) upon RSV an infection in adults. Within the current research, neonatal C57BL/6 AMs mobilized very weakly the IFN-I pathway upon RSV an infection in vitro and did not restrain virus replication.

Leave a Reply

Your email address will not be published. Required fields are marked *